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ABSTRACT 
The interaction between drugs and excipients or between drugs and other 
drugs in the same dosage form have potential to modify safety and efficacy. 
In some cases the interaction can be of such a degree as to preclude the use 
of some excipients or to dramatically reduce the shelf life of the products. 
Thus there is clearly a need for techniques which can reduce or eliminate 
such interactions. 
Sometimes the irrational combination of two drugs or drug and excipient 
cause a decrease in the stability, bioavailability and efficacy of the dosage 
form 1 .. Microencapsulation can be considered as a tool to enhance the drug 
stability 2. It has generally been observed that microencapsulated products 
show a substantial reduction or elimination of the adverse effects of 
incompatibilities, although quantitative data on the extent of stabilization is not 
readily available in the published literarture. 
The primary objective of this study was to determine the drug interactions and 
incompatibilities between drugs and excipients which are widely used in 
pharmaceutical manufacturing and have some characteristic compatibility 
problems. I did these studies on powder mixes and compressed tablets owing 
to the fact that majority of the dosage forms are formulated in the solid state 
3 .. The study included three drugs namely aspirin, acetaminophen and 
pseudoephedrine ( hydrochloride salt ). 
The interaction between aspirin and dibasic calcium phosphate ( 
Emcompress) was studied in detail. Non - microencapsulated aspirin showed 
significant degradation by hydrolysis in presence of Emcompress at room 
temperature as well as elevated temperature. Microencapsulated aspirin 
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showed a marked decrease in the degradation under same conditions.The 
stabilizing effect of the microencapsulation was both statistically significant 
and substantial. 
The interaction between acetaminophen ( APAP ) and diphenhydramine 
hydrochloride and phenylephrine hydrochloride was monitored for the 
presence of degradation products. These agents showed incompatibility with 
acetaminophen when used in the proportion which was the same as that of an 
over the counter product. The manifestation of incompatibility was melting 
point depression by eutectic formation. The eutectic formation was prevented 
when microencapsulated acetaminophen was used. 
Non - microencapsulated acetaminophen showed significant adsorption over 
antacids like aluminum hydroxide, magnesium trisilicate and calcium 
carbonate. Microencapsulated acetaminophen demonstrated appreciable 
decrease in the rate and extent of adsorption under similar conditions. 
I had planned the compatibility studies of pseudoephedrine HCI with hydrous 
lactose and with sodium metabisulphite. The literature showed evidence of 
some degradation products. However initial tests showed no significant 
compatibility problems and hence no further experimentation was performed 
on these substances. However the interaction of pseudoephedrine and 
acetaminophen and pseudoephedrine and aspirin was monitored for the 
degradation products. 
A battery of in process quality control tests such as appearance, weight 
variation, content uniformity, surface characters, flowability, friability, and 
moisture content were performed on all three formulations. All results were 
evaluated using conventional statistical techniques using factorial design and 
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the differences between microencapsulated and non microencapsulated 
products were determined at 95 % confidence intervals. Both the groups were 
compared using tests such as ANOVA ( Analysis of Variance ), Student's t 
test ( two tailed ), and simple regraession analysis with the help of a software 
on a microcomputer. 
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STUDY OF MICROENCAPSULATED PRODUCTS WITH RESPECT TO 
THEIR ABILITY TO PREVENT INCOMPATIBILITIES 
1 
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ABSTRACT 
The primary objective of this study was to determine the drug interactions and 
incompatibilities between the drugs and drugs and excipients which have 
some characteristic compatibility problems. This study included three of such 
drugs namely aspirin, acetaminophen ( APAP ) and pseudoephedrine 
hydrochloride. It consisted of series of comparative laboratory experiments for 
the manifestation of incompatibilities or lack thereof in ( 1 ) powder mixes and 
(2 ) compressed tablets. The selected drugs were used as powders and in the 
form of microencapsules. The study was conducted at room temperature as 
well as at 40 C and 60 % R. H. (relative humidity) 
The important degradation pathway for aspirin is hydrolysis. The hydrolysis of 
aspirin in presence of dibasic calcium phosphate was studied. Aspirin 
hydrolized producing 39 % degradation at room temperature and 53% at 
elevated temperature. In case of microencapsulated aspirin sample, it was 26 
% at room temperature and 28 % at elevated temperature. All samples were 
analyzed initially and after three months. The avarage salicylic acid build up in 
both cases was under the pharmacopoeal limits. 
The interaction of acetaminophen with various antacids was monitored. The 
manifestation of interaction was the adsorption of the drug on the antacid. The 
antacids tested were calcium carbonate ( 1 ) , aluminum hydroxide ( 2 ) and 
magnesium trisilicate ( 3 ). In case of non - microencapsulated 
acetaminophen sample the adsorption of the drugs was found to be 7 % on 
(1 ), 18 % on ( 2 ) and 15 % on ( 3 ). In case of microencapsulated 
acetaminophen sample the adsorption was 2 % on ( 1 ), 1.5 % on ( 2 ) and 
1.6 % on ( 3 ). The interaction between acetaminophen with diphenhydramine 
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hydrochloride and phenylephrine hydrochloride was characterized by melting 
point depression due to eutectic formation. The eutectic formation was not 
observed in microencapsulated acetaminophen samples. From these studies 
conclusion was made that microencapsulated samples showed substantial 
reduction and in some cases, elimination of the adverse effects of 
incompatibilities. 
3 
INTRODUCTION 
Microencapsulation may be thought of as a method of wrapping small entities 
in individual protective coatings 4. In microencapsulation a relatively thin 
coating is applied to small particles of solids or droplets of liquids and 
dispersions. It is arbitrarily differentiated from macroencapsulation in that the 
former involves the coating of the particles ranging dimmensionally from 
several tenths of a micrometer to about 5000 µ. 5,6. 
In pharmaceutical preparations the uniqueness of microencapsules lies in the 
size of the coated particles and their subsequent use and adaptation to a wide 
variety of dosage forms 8. Due to the use of these discrete particles, drug 
moieties can be widely distribiuted throughout the gastrointestinal tract. This 
potentially improves drug absorption and reduces side effects related to 
localized build up of irritating drugs against the gastrointestinal mucosa. 
In the U. S. A. the majority of the drugs which are in over the couter (OTC ) 
market are combination products 9. Sometimes the irrational combination of 
two drugs or drug - excipient leads to a decrease in the stability, bioavailability 
and efficacy of the dosage form 1 O. It has generally been observed that 
microencapsulated products show a substantial reduction or elimination of the 
adverse effects of incompatibilities, however the published literature does not 
appear to have quantitative data substantiating this point. 
The compatibility studies mentioned above involved powder mixes and tablet 
dosage forms owing to the fact that majority of the dosage forms are 
formulated in the solid state 11. Any reaction occuring in the solid state will 
assume dramatically different characteristics from the same reaction 
4 
proceeding under a liquid or gaseous state 12. Solid state reaction have long 
maintained a poorly defined terrain on chemical landscape. However difficult 
to define quantitatively, interactions between solids present a new frontier in 
the investigation in the chemical behaviour. The primary objective of this 
study was to determine the drug interactions and incompatibilities between 
drugs and excipients which are widely used in the pharmaceutical 
manufacturing and have some characteristic compatibility problems. This 
study included three of such commercially important drugs. They are aspirin, 
acetaminophen and pseudoephedrine hydrochloride. 
A literatute search has shown that these drugs have some characteristic 
compatibility problems with commonly used excipients such as dibasic 
calcium phosphate ( Emcompress ) 13 , hydrous lactose 14 ,sodium 
metabisulphite and magnesium stearate 15 . There is also a sufficient 
evidence that these drugs interact with other classes of drugs such as 
antacids, antihistamines and decongestants. This study involved calcium 
carbonate, aluminum hydroxide and magnesium trisilicate as antacids, 
diphenhydramine hydrochloride as antihistaminic and phenylephrine 
hydrochloride as decongestatnt. Solid dosage forms containing aspirin, 
acetaminophen and pseudoephedrine comprise a significant portion of todays 
OTC market. Thus it becomes very important to investigate the field of drug 
interactions occuring in these drugs if they are to be formulated in the solid 
dosage forms. 
5 
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MATERIALS AND METHODS 
This study involved a series of comparative laboratory experiments for the 
manifestation of incompatibilities or lack thereof in 
a } Powder mix es 
b} Direct compression tablets. 
The selected drugs were used as powders and in the form of 
microencapsules. The laboratory investigation was made in four types of 
systems for each drug. 
a} Powder mixes using non - microencapsulated drug. 
b} Powder mixes using microencapsulated drug. 
c } Compressed tablets made using non - microencapsulated drug. 
d} Compressed tablets made using microencapsulated drug. 
The non - microencapsulated and microencapsulated drugs were obtained 
from Eurand America, Vandalia, Ohio. All other materials were purchased 
from commercial sources, mainly from Fisher Scientific, Springfield, New 
Jersey. All other solvents and reagents used were of HPLC grade. 
The powders and tablets of the three drugs were evaluated at the time of 
preparation in terms of potency, flowability, appearance, hardness, friability, 
weight variation and content uniformity. They were also evaluated at intervals 
during storage at ambient temperature and also at 40 o C I 60 % relative 
6 
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humidity for a period of eight weeks in order to determine the ralative rate of 
change between both the types of systems. 
The following methods were used for the camparision of microencapsulated 
and non - microencapsulated formulations. 
1 ) Macroscopic evaluation : 
Samples were subjected to visual observation in triplicate. The macroscopic 
observation was done for the determination of possible changes in 
crystalinity, liquifaction, hygroscopicity etc. 
2) Dissolution tests: 
Dissolution tests were carried out by using Vanderkamp dissolution test 
apparatus with standard USP basket assembly. The dissolution medium was 
distilled water and the studies were done at 37 o C. at 100 RPM. 
3 ) Ultra Violet Spectroscopy ( UV ) : 
Ultra violat spectroscopy was used to monitor the interaction between aspirin 
and dibasic calcium phosphate ( Emcompress ). It was also used for the 
quantification of the interaction between acetaminophen and vario.us antacids. 
The antacids used were aluminum hydroxide, calcium carbonate and 
magnesium trisilicate. 
For the intercation between aspirin and dibasic calcium phosphate, the 
samples were prepared by mixing equal portions of aspirin and Emcompress. 
They were then mixed in a turbula mixer for about one hour. Portions of 200 
mg. were taken in 5 ml. open vials. The vials were placed in constant 
temperature and relative humidity ( 45 o C. and 55 % A. H. ). They were then 
7 
removed initially and then at at regular time intervals and analyzed 
spectrophotometrically in 95 % ethanol at 302 nm. 
The validation of the assay was done in order to determine the content of 
salicylic acid which is a degradation product of aspirin hydrolysis.The method 
employed was as follows. UV absorbance spectra of aspirin and salicylic acid 
were obtained for determination of their respective lambda max. They were 
258 and 302 nm. respectively. Samples were removed initially and then at 
regular time intervals. They were diluted appropriately with ethanol and 
analyzed spectrophotometrically by Hawlett Peckard 8451 A diode array 
spectrophotometer. The amount of salicylic acid formed was determined by 
the method of simultaneous equations using molar absorptivities. 
Elaborate study was performed on the interaction of acetaminophen with 
different antacids. The UV determination was done as follows. A standard 
calibration curve was plotted for both, the microencapsulated and non -
microencapsulated acetaminophen each time befor the intercation with each 
antacid. Specific amount of drug solution was mixed with antacid and was 
rotated in a rotating assembly at 37 o C. at 60 RPM. The contents were 
filtered by nylon 6 filter membrane with a pore soze of 0.45 µ.and analyzed 
spectrophotometrically at 244 nm. Blank correction was done each time and 
for each antacid to eliminate the influence of water soluble impurities present 
in the antacid. Attempt was made to determine if there is prevention or 
decrease in adsorption due to microencapsulation. 
8 
4 ) Differential Scanning Calorimetry ( DSC ) : 
Differential scanning calorimetry was used for the determination of the 
interaction between acetaminophen and diphenhydramine hydrochloride and 
acetaminophen and phenylephrine hydrochloride. Work was done upon both, 
microencapsulated and non-microencapsulated acetaminophen. The 
instrumentation was Perkin Elmer DSC - 2 with Linear 1200 chart recorder. 
The heating rate was 5 o C I min. and the temperature range was 30 ° C. to 
250 o C. The chart speed was 2 cm I sec. and the sensetivity of the instrument 
was 1 O m. cal. I deg. The experiment was carried our in an inert atmosphere 
with the supply of nitrogen gas. About 25 mg. of sample was subjected to 
DSC each time. The content uniformity of the samples were determined by 
the endothermic peaks obtained. The results were obtained in duplicates. The 
manifestation of interaction between acetaminophen and above mentioned 
drugs was melting point depression due to the formation of eutectic mixture. 
Attempt was made to determine if there is prevention or decrease in the 
severity of the interaction due to microencapsulation. 
5 ) Scanning Electron Microscopy ( SEM ) : 
The microencapsules of aspirin, acetaminophen and pseudoephedrine were 
mounted on a carbon tape and sputter coated with Gold : Palladium ( 60 : 40 ) 
in an Edward's S150 B sputtum coater. The analysis was done by examining 
the samples in the scanning mode with a JEOL 1200 EX scanning I 
transmission electron microscope operating at 60 KV. 
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6 ) Statistical Evaluation : 
Statistical evaluation of the interaction between aspirin and dibasic calcium 
phosphate was done using Student's t test with a a value of 0.01. The 
evaluation of the interaction between the acetaminophen and various antacids 
was done by using Analysis Of Variance ( ANOVA ). 
10 
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RESULTS 
Figure 1 to 3 shows the scanning electron micrographs ( SEM ) of the 
microencapsules of aspirin, acetaminophen and pseudoephedrine 
hyd roch lo ride respectively. 
Fig. 1 gives the micrograph of aspirin, characterized by regular needle shaped 
crystals ranging from 500 to 2000 microns in length and 25 to 200 microns in 
width. The coat over these crystals is evident as seen in the photograph. We 
also found some small irregular crystals clustered in a group between the 
large needle shaped crystals. Some surface irregularities are also seen in the 
micrograph. 
Fig. 2 gives SEM of microencapsulated acetaminophen. The sample is 
characterized by small irregular crystals clustered in a group. The average 
size ranges from 100 to 500 microns in length and about 50 to 300 microns in 
width. The coating over the crystals appear to be thick and smooth. 
Figure 3 represents SEM of pseudoephedrine hydrochloride. The sample 
consists of needle shaped round and irregular crystals ranging from 100 to 
750 microns in length. The coating of the encapsulating material is seen 
clearly from the photograph.SEM profile analysis was done at 50, 200 and 
3000 times magnification. 
Figure 4 shows differential scanning thermogram of non - microencapsulated 
acetaminophen ( 1 ), diphenhydramine hydrochloride ( 2 ) and 1 : 1 physical 
mixtre. Non - microencapsulated acetaminophen showed a characteristic 
11 
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endothermic peak at 172 o C. Diphenhydramine hydrochloride showed a peak 
at 167 o C. When 1 : 1 physical mixture was subjected to DSC, the 
endothermic peak is observed at 98 o C. Figure 5 shows differential scanning 
thermogram for the microencapsulated acetaminophen (1 ), diphenhydramine 
hydrochloride ( 2 ) and 1 : 1 physical mixture ( 3 ). The microencapsulated 
acetaminophen showed an endothermic peak at 173 ° C. The 1 : 1 physical 
mixture showed broad endothermic peak between 143 to 146 ° C.Figure 6 
shows DSC thermogram for the acetaminophen - phenylephrine 
hydrochloride combination. It shows an endothermic peak at 172 ° C for non 
microencapsulated acetaminophen ( 1 ), 147 o C for phenylephrine 
hydrochloride ( 2) and 122 o C for1 : 1 physical mixture (3) 
Figure 7 represents the DSC thermogram when acetaminophen is 
microencapsulated. The micrpencapsulated acetaminophen showed a peak 
at 172 o C. 1 : 1 physical mixture showed endothermic peak at 152 o C. 
Table 1 shows percentage degradation of aspirin in presence of dibasic 
calcium phosphate in powder mixes. The concentration range was 5 µg I ml. 
to 25 µg I ml The mean percentage degradation was found to be 42 % at 
room temperature and 54 % at elevated temperature for non -
microencapsulated aspirin. For aspirin microencapsules the values were 27 % 
and 33 % respectively. The two treatments were compared using Student's t 
test.( Table 4 }.The p value for this statistic was found to be 0.004 indicating 
that the probability that there is no difference between the two data sets is 
0.004. 
Table 2 shows percentage degradation of aspirin in presence of Emcompress 
in direct compression tablets. Same concentration range as in case of powder 
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mixes was selected. The mean percentage degradation in this case was 
found to be 39 % at room temperature and 53 % at elevated temperature 
when non- microencapsulated aspirin was used. In case of 
microencapsulated aspirin the values were 26 % and 28 % respectively. 
When the two treatments were compared with Student's t test (Table 4 ). The 
p value was found to be 0.006 %. 
Figure 8 shows the dissolution profile of non-microencapsulated and 
microencapsulated acetaminophen tablets at room temperature in presence 
of aluminum hydroxide. Figure 9 shows the dissolution profile of non 
microencapsulated and microencapsulated acetaminophen tablets at 
elevayed temperature in presence of aluminum hydroxide. For non -
microencapsulated acetaminophen, the percentage dissolution after 45 
mins.was 78 % for the samples kept at room temperature and 82 % for 
samples kept at elevated temperature. For microencapsulated 
acetaminoiphen the values were found to be 94 % and 95 % respectively. As 
seen from figures 8 and 9, all the profiles were compared with acetaminophen 
control. 
Figure 1 O shows dissolution profile of non-microencapsulated and 
microencapsulated acetaminophen tablets at room temperature in presence 
of calcium carbonate. Non - microencapsulated acetaminophen showed 89 % 
dissolution for samples kept at room temperature and 90 % dissolution for 
samples stored at elevated temperature. Figure 11 shows dissolution profile 
of non - microencapsulated and microencapsulated acetaminophen tablets at 
elevated temperature in presence of calcium carbonate. For 
microencapsulated acetaminophen the percentage dissolution was 94 % for 
samples stored at room temperature and 97 % for the samples stored at 
13 
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elevated temperature. Both the dissolution profiles were compared with 
acetaminophen control. 
Figure 12 shows dissolution profile of non - microencapsulated and 
microencapsulated acetaminophen tablets at room temperature in presence 
of magnesium trisilicate. The percentage dissolution was 82 % for the 
samples kept at room temperature and 83 % for the samples kept at elevated 
temperature. Figure 13 shows dissolution profile of non - microencapsulated 
and microencapsulated acetaminophen tablets at elevated temperature in 
presence of magnesium trisilicate. Microencapsulated acetaminophen 
showed 94 % dissolution for the samples kept at room temperature and 94 % 
dissolution for the samples kept at elevated temperature. Both the dissolution 
profiles were compared with acetaminophen control. 
Table 3 shows the interaction of acetaminophen with different antacids in the 
powder mixes. In case of non microencapsulated acetaminophen and 
aluminum hydroxide powder mix the percentage of drug adsorbed over the 
antacid was found 14 %. Use of microencapsulated acetaminophen 
decreased this adsorption to 4 %. Similarly for non - microencapsulated and 
microencapsulated acetaminophen with aluminum hydroxide mix the values 
were 5 % and 2 % respectively. When the antacid was magnesium trisilicate, 
the values were 24 % and 8 % respectively.The statistical evaluation of these 
interactions was done by using ANOV A. (Analysis of Variance ) Tables 5 , 6 
and 7 shows the results obtained form ANOV A. 
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FIGURE 1 Scanning electron micrograph of the crystals of microencapsulated 
aspirin ( magnified 50 times ) taken with a JEOL 1200 EX electron 
microscope. 
15 
FIGURE 2 Scanning electron micrograph of the crystals of microencapsulated 
acetaminophen ( magnified 50 times ) taken with a JEOL 1200 EX electron 
microscope. 
16 
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FIGURE 3 Scanning electron micrograph of the crystals of microencapsulated 
pseudoephedrine hydrochloride ( magnified 50 times ) taken with a JEOL 
1200 EX electron microscope. 
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TABLE 1 Percentage degradation of aspirin in presence of dibasic calcium 
phosphate ( Emcompress) in powder mixture: 
Concentration Non micro - Non micro - Aspirin micro- Aspirin micro-
encapsulated encapsulated encapsules encapsules 
as_Qirin as_Qirin 
Samples at samples at sample at samples at 
room tem..e: elevated tern..e: room tem..e: elevated temQ. 
5 µg. I ml. 43% 55% 37% 40% 
1 O J.l.9· I ml. 48% 59% 25% 33% 
15 _gg_. I ml. 36% 47% 21 % 28% 
20 µg. I ml. 44% 51 % 24% 30% 
25 µg. I ml. 39% 49% 27% 25% 
Mean 424% 54.8% 27.1 % 33.5% 
S. D. 9.2 11.2 6.2 6.2 
18 
( 
( 
( 
TABLE 2: Percentage degradation of aspirin in presence of dibasic calcium 
phosphate ( Emcompress ) in direct compression tablets: 
Concentration Non micro - Non micro - Aspirin micro - Aspirin micro -
encapsulated encapsulated encapsules encapsules 
as_Qirin as_Qirin 
Samples at Samples at Samples at Samples at 
room tem_Q_. elevated tem_Q_. room tem_Q_. elevated tem_Q. 
5 µg. I ml. 42% 55% 31 % 40% 
10 µg. I ml. 41 % 57% 35% 33% 
151!9_. I ml. 34% 55% 20% 29% 
20 µg. I ml. 38% 49% 20% 27% 
251!9_. I ml. 40% 51 % 25% 24% 
Mean 39.1 % 53.4% 26.4% 28.1 % 
S.D. 6.3 8.6 10.3 11.2 
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TABLE 3 : Interaction of acetaminophen with various antacids in the powder 
form 
Combination Percentage drug adsorbed on antacid 
Unencapsulated acetaminophen and 14% 
aluminum h_ydroxide 
Encapsulated acetaminophen and 4% 
aluminum h_ydroxide 
Unencapsulated acetaminophen and 5% 
calcium carbonate 
Encapsulated acetaminophen and 2% 
calcium carbonate 
Unencapsulated acetaminophen and 24% 
ma_g_nesium trisilicate 
Encapsulated acetaminophen and 8% 
magnesium trisilicate 
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TABLE 4 : Student's t test for microencapsulated and non - microencapsulated 
aspirin in presence of Emcompress 
a ) Powder mix es 
Non - microencapsulated Vs microencapsulated at room temperature 
De_g_. of Freedom Mean X - Y Paired t value Prob. J_ 2 - tail 1 
4 15.2 5.084 0.0071 
N on - m 1croencapsu ate dV s m1croencapsu ate d ate evate d tern _Q_erature. 
De~ of Freedom Mean X - Y Paired t value Prob. ( 2 - tail 1 
4 21 10.917 0.0004 
b) Direct compression tablets 
Non - microencapsulated Vs microencapsulated at room temperature 
De~ of Freedom Mean X - Y Paired t value Prob ( 2 - taill 
4 12.8 6.291 0.0033 
N I t d V on - m1croencapsu a e It d t I t dt s m1croencapsu a e a e eva e t em_.e_era ure 
De_g_. of Freedom Mean X - Y Paired t value Prob ( 2 - taill 
4 22.8 10.701 0.004 
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FIGURE 4 Differential scanning calorimeter thermogram of non 
microencapsulated acetaminophen ( labelled as 1 ) , Diphenhydramine 
hydrochloride ( Labelled as 2 ) and 1 : 1 physical mixture of the two drugs. 
(labelled as 3). The scale at the bottom shows temperature in degree 
centigrades. 
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FIGURE 5 Differential scanning calorimeter thermogram of 
microencapsulated acetaminophen ( labelled as 1 ) , Diphenhydramine 
hydrochloride (Labelled as 2) and 1 : 1 physical mixture of the two drugs. 
(labelled as 3). The scale at the bottom shows temperature in degree 
centigrades. 
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FIGURE 6 Differential scanning calorimeter thermogram of non 
microencapsulated acetaminoiphen ( labelled as 1 ) , Phenylephrine hydro -
chloride ( labelled as 2 ) and 1 : 1 physical mixture ( labelled as 3 ). The scale 
at the bottom shows the temperature in degrees centigrade. 
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FIGURE 7 Differential scanning calorimeter thermogram of non 
microencapsulated acetaminoiphen ( labelled as 1 ) , Phenylephrine hydro -
chloride (labelled as 2) and 1 : 1 physical mixture (labelled as 3 ). The scale 
at the bottom shows the temperature in degrees centigrade. 
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TABLE 5: ANOVA of microencapsulated and non - microencapsulated 
acetaminophen in presence of aluminum hydroxide 
Source of Degree of Sum of Mean F value P value 
variation Freedom s_g_uares square 
Temperature 1 5.311 5.311 142.5 0.00 
Formulation 1 0.113 0.113 3.045 0.0963 
TF 1 0.711 0.711 19.075 0.0003 
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TABLE 6: ANOVA of microencapsulated and non - microencapsulated 
acetaminophen in presence of calcium carbonate 
Source of Degree of Sum of Mean F value P value 
variation Freedom squares square 
Temperature 1 0.211 0.211 9.209 0.0065 
Formulation 1 0.155 0.155 6.776 0.0065 
TF 1 3.912 3.912 170.8 0.00 
31 
( 
( 
TABLE 7 : ANOVA of microencapsulated and non - microencapsulated 
acetaminophen in presence of magnesium trisilicate 
Source of Degree of Sum of Mean F value P value 
variation Freedom s_g_uares s_g_uare 
Temperature 1 8.821 8.812 419.0 0.00 
Formulation 1 0.886 0.886 42.11 0.00 
TF 1 0.760 0.760 36.13 0.00 
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FIGURE 8 Comparision of the dissolution profiles of non microencapsulated 
and microencapsulated acetaminophen tablets at room temperature in 
presence of aluminum hydroxide. The abscissa indicates time in minutes and 
the ordinate shows cumulative percent release of the drug. The 
acetaminophen control is labelled as APAP CONTROL where as the 
dissolution profiles of non microencapsulated and microencapsulated 
acetaminophen are labelled as N. M. AT R. T. and M. AT R. T respectively. 
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FIGURE 9 Comparision of the dissolution profiles of non microencapsulated 
and microencapsulated acetaminophen tablets at elevated temperature in 
presence of aluminum hydroxide. The abscissa indicates time in minutes and 
the ordinate shows cumulative percent release of the drug.The 
acetaminophen control is labelled as APAP CONTROL where as the 
dissolution profiles of non microencapsulated and microencapsulated 
acetaminophen are labelled as N. M. ATE. T. and M. ATE. T. respectively. 
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FIGURE 10 Comparision of the dissolution profiles of non microencapsulated 
and microencapsulated acetaminophen tablets at room temperature in 
presence of calcium carbonate.The abscissa indicates time in minutes and 
the ordinate shows cumulative percent release of the drug.The 
acetaminophen control is labelled as APAP CONTROL where as the 
dissolution profiles of non microencapsulated and microencapsulated 
acetaminophen are labelled as N. M. AT R. T. and M. AT R. T. respectively. 
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FIGURE 11 Comparision of the dissolution profiles of non microencapsulated 
and microencapsulated acetaminophen tablets at elevated temperature in 
presence of calcium carbonate The abscissa indicates time in minutes and 
the ordinate shows cumulative percent release of the drug.The 
acetaminophen control is labelled as APAP CONTROL where as the 
dissolution profiles of non microencapsulated and microencapsulated 
acetaminophen are labelled as N. M. ATE. T. and M. ATE. T. respectively. 
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FIGURE 12 Comparision of the dissolution profiles of microencapsulated and 
non microencapsulated acetaminophen in the tablet form at room temperature 
in presence of magnesium trisilicate.The abscissa indicates time in minutes 
and the ordinate shows cumulative percent release of the drug.The 
acetaminophen control is labelled as APAP CONTROL where as the 
dissolution profiles of non microencapsulated and microencapsulated 
acetaminophen are labelled as N. M. AT R. T. and M. AT R. T. respectively. 
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FIGURE 13 Comparision of the dissolution profiles of microencapsulated and 
non microencapsulated acetaminophen in the tablet form at elevated 
temperature in presence of magnesium trisilicate. The abscissa indicates time 
in minutes and the ordinate shows cumulative percent release of the drug.The 
acetaminophen control is labelled as APAP CONTROL where as the 
dissolution profiles of non microencapsulated and microencapsulated 
acetaminophen are labelled as N. M. ATE. T. and M. ATE. T. respectively. 
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DISCUSSION 
In all the interaction studies carried out, it was demonstrated successfully that 
the microencapsulated drugs showed substantial reduction of the adverse 
effects of incompatibilities. The rate of degradation was significantly different 
for the microencapsulated and non microencapsulated systems. Though 
literature sources support the concept of enhancement of drug stability due to 
microencapsulation, there is absence of reliable published quantitative data 
which proves this point. Lot of material addresses this issue qualitatively. This 
study was focused on the quantitative aspects of the enhancement of stability 
due to microencapsulation. 
All three drugs examined in this project showed significant stability when 
incorporated to microencapsules. However the level of protection was found 
to be different in all three cases. For acetaminophen the degree of protection 
was greatest followed by pseudoephedrine and aspirin. It was found that the 
level of protection offered by microencapsulated drugs in compressed tablets 
was greater than those found in the powder mixes. At the same time, the 
severity of the interaction was less in case of powders and was greater in 
case of compressed tablets. In case of tablets it was found that there was no 
effect of the compaction force on the integrity of the microcapsule coat. This 
observation could be supported by the fact that the tablets contained large 
amount of lactose which was used as a tablet matrix. This may have 
dispersed microencapsules and might have provided a cushioning effect 
which would protect the microencapsules from rupture during the compaction 
process. It would be interesting to see the effect of compaction force when the 
percentage of lactose to the microcapsules gradually decreases i. e. in a 
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tablet the amount of lactose goes on decreasing and the amount of drug 
remains same. 
It was also observed that for the three compaction forces selected, the 
integrity of microcapsules was unaffected. This finding suggests that the 
Eurand microencapsules are sufficiently robust to be used commercially in 
compressed tablets without concern for capsule rupture. It may also be 
interesting to determine the effect of the increase in the percentage of 
microcapsules over the range of compaction forces. 
It was found that the temperature affects significantly the results obtained 
between microencapsulated and non microencapsulated systems. The effect 
of time was not that pronounced. This observation was supported by the fact 
that the samples at elevated temperature were subjected to rigorous stress 
conditions ( 45 o C and 60 % relative humidity). 
The decomposition of aspirin is due to hydrolysis which gave salicylic acid as 
a major hydrolytic product. The interaction takes place at room temperature 
and the rate of the reaction was enhanced by the increase in the temperature 
or the presence of moisture. The interaction was monitored in both these 
conditions. The assay involved the determination of the amount of drug 
remaining over an interval of time in powder mixes and compressed tablets. 
The analysis was done by UV at A. max. for aspirin. The figures obtained from 
both the data sets were compared and it was concluded that the degree of 
protection offered by microencapsulation was more in compressed tablets 
than in powders. 
The interaction of acetaminophen with various antacids was a physical 
phenomenon of adsorption of the drug over the antacid. As indicated earlier 
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the rate of interaction differed significantly in powder form and compressed 
tablets. It was also found that the degree of adsorption was less at elevated 
temperature and more at room temperature. This observation can be 
supported by the fact that adsorption is a physical phenomenon and is 
affected by kinetics. The increase in temperature may result in the increase in 
the kinetic energy of the molecules, thereby increasing internal energy 
facilitating desorption. 
It was observed that there is practically no interaction between aspirin and 
pseudoephedrine combination as well as pseudoephedrine acetaminophen 
combination. The inertness of the combination was apparent by the UV 
absorbance readings as well as by physical observations. The stability of the 
combination was retained at accelerated conditions. As pseudoephedrine 
itself was found to be stable with aspirin and acetaminophen, the same 
conclusion holds good for microencapsulated pseudoephedrine as the coating 
is made up of inert material. 
The interactions of aspirin and pseudoephedrine were analyzed using 
statview statistical package. The method of analysis was Student's two tailed 
t test. Using this test, the difference in the microencapsulated and non -
microencapsulated systems was easily demonstrated. The ex. value for this 
statistic was 0.01. The probability term calculated by t test was found very 
near to 0 indicating there is a very low probability that the results are similar 
between non microencapsulated and microencapsulated systems. 
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CONCLUSIONS 
The conclusions made from the drug interaction studies can be enumarated 
as follows. 
1 ) Aspirin showed significant degradation due to hydrolysis with Emcompress 
in powder mixes and direct compression tablets. The severity of this 
interaction was substantially reduced for aspirin in microencapsules 
2) Aspirin does not show any compatibility problems when combined with 
acetaminophen. The combination is stable and does not show degradation in 
powder mixes as well as compressed tablets. 
4 ) Aspirin does not interact with pseudoephedrine. Although the literature 
mentions the possibility of epimerization it was not observed in the laboratory 
experiments. The samples of aspirin - pseudoephedrine mixture were stable 
at room temperature as well as elevated temperature. 
5) Acetaminophen reacts with antacids resulting in the adsorption of the drug 
over the antacid. The antacids tested were aluminum hydroxide, calcium 
carbonate and magnesium trisilicate. The severity of the interaction was found 
to be maximal in case of magnesium trisilicate and least in calcium 
carbonate. The response was similar in both powder mixes and compressed 
tablets. This interaction was eliminated completely when the drug was 
formulated in APAP Eurand microencapsules 
6 ) There exist a characteristic interaction between acetaminophen and 
phenylephrine HCL & diphenhydramine HCL. Acetaminophen formed a 
eutectic mixture with these drugs resulting in melting point depression. 
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Microencapsules of acetaminophen gave physical protection against eutectic 
formation for both the drugs tested. 
7) Pseudoephedrine does not show any interaction with acetaminophen and 
the mixture of these were found stable at room temperature as well as 
accelerated conditions. Microencapsulated acetaminophen gave similar 
results. 
8 ) The statistical evaluation shows that there is a significant difference 
between the data sets obtained by the microencapsulated and non 
microencapsulated systems. 
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APPENDIX A 
Appendix A contains various calibration curves of microencapsulated and non -
microencapsulated drugs.( Fig 1 to Fig 6 ). The method used for plotting the 
calibration curves involved UV spectrophotometric determinations at various 
concentrations. The absorbance values were determined at various 
concentrations and plotted as ordinates. 
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FIGURE 1 : Calibration curve of non - microencapsulated aspirin 
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FIGURE 2 : Calibration curve of microencapsulated aspirin. 
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Figure 3 : Calibration curve of non microencapsulated acetaminophen. 
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Figure 4 : Calibration curve of microencapsulated acetaminophen 
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Figure 5 : Calibration curve of non microencapsulated pseudoephedrine hydrochloride. 
0.8 y = 6.1279e-4 + 8.8718e-4x R"2 = 0.999 
0.6 
o.o-a----r----..,.---r-----r-----r--r-----r-----. 
0 200 400 600 800 
Concentration in µg I ml. 
·~ 
Figure 6 : Calibration curve of microencapsulated pseudoephedrine hydrochloride 
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APPENDIX B 
Appendix 8 ( Fig 7 to Fig 9) contains Scanning electron micrographs of aspirin, 
acetaminophen and pseudoephedrine hydrochloride at higher magnifications ( 
200 and 3000 ) times. The procedure for obtaining these SEM is same as the 
one discussed under materials and methods. 
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FIGURE 7 : Scanning electron micrographs ( magnified 200 and 3000 
times ) of aspirin microencapsules 
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FIGURE : 8 Scanning electron micrographs of acetaminophen ( magnified 
200 and 3000 times ) microencapsules. 
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FIGURE 9 : Scanning electron micrographs of pseudoephedrine hydro 
chlOiide (magnified 200 and 3000 times) microencapsules 
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APPENPIXC 
Appendix C contains 
1 ) Dissolution data of acetaminophen with various antacids (Tables 1 to 3) in 
tablets. 
2 ) UV analysis for the validation of the interaction between aspirin and 
Emcompress, for the determination of salicylic acid content. (Tables 4 to 8) 
3) Calibration curve data for the figures in appendix A.( Tables 9 to 14 ). 
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TABLE 1 Dissoultion data of acetaminophen and aluminum hydroxide 
( tablets 
Time in mins. unencapsulated unencapsulae:J Encapsulated Encapsulated 
aceamin~en aceamin~en aceaminophen acetamin~ICI' I 
Samples at Samples at Samples at samples at 
room tem_Q. elevated tem_Q_. room tem_Q. elevated terTIQ. 
5 9.30% 9.83% 10.53 % 10.36 % 
10 33.87% 36.42 % 34.30 % 35.37% 
15 45.86 % 47.96 % 48.22 % 49.96 % 
( 
20 66.28 % 68.68 % 67.80 % 68.31 % 
25 68.37 % 70.57 % 75.90 % 78.15 % 
30 73.42 % 80.25 % 88.14 % 90.60 % 
45 78.01 % 81.63 % 93.68 % 95.32 % 
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TABLE 2: Dissoultion data of acetaminophen and calcium carbonate tablets: 
Time in mins. UnencapsulaEd UnencapsulaEd Encapsulated Encapsulated 
acetamif!QQb_en acetamin_.QQb_en acetaminophen acetaminoprlt:'ll 
samples at Samples at Samples at Samples at 
room tem_E: elevated tem_Q_. room tem_E: elevated terTIQ. 
5 9.47% 10.36 % 10.30 % 9.84% 
10 33.47 % 34.54 % 37.49 % 36.84% 
15 45.69 % 46.87 % 51.55 % 51.76 % 
20 62.67% 66.67 % 70.41 % 69.64% 
25 69.13 % 77.69 % 79.95 % 80.63 % 
30 84.68 % 87.91 % 92.53 % 91.05 % 
45 89.26 % 90.26 % 94.25 % 96.73 % 
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TABLE 3 : Dissolution data of acetaminophen and magnesium trisilicate 
tablets: 
Time in mins. Unencapsulaed Unencapsulaed Encapsulated Encapsulated 
aooemin~en aootlmi~en aooem~en aootaminophen 
Samples at samples at Samples at Samples at 
room tem_Q. elevated tem_Q. room tem_Q. elevated tem_Q. 
5 8.91 % 9.66% 10.44 % 10.63 % 
10 34.13 % 34.18 % 35.92 % 37.07% 
15 47.00 % 47.86 % 50.94 % 51.54% 
20 65.97 % 66.71 % 68.60 % 69.92 % 
25 70.29 % 70.78 % 78.71 % 80.18 % 
30 75.83 % 78.47 % 91.97 % 94.02 % 
45 81.84 % 83.28 % 94.21 % 94.95 % 
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Calculations for the determination of salicylic acid formed in the samples of 
aspirin by the method of simultaneous equations 
Week 1 
A 258 = 0.1631 = 258 a aspirin * b * c aspirin + 258 a sal. acid * b * c sal. 
acid 
A 302 = 0.002334 = 302 a aspirin * b * c aspirin + 302 a sal acid * b * c sal. 
acid 
putting the values for absorptivities as per Table 4 we get two simultaneous 
equations in two unknowns 
0.1631 = 0.00695 C a + 0.00157 C s --------------------------------------- ( 1 ) 
0.002334 = 0.00035 C a + 0.0276 Cs -------------------------------------- ( 2 ) 
Multiplying equation 2 by 19.85 we get 
0.0463 = 0.00695 C a+ 0.05488 C s -------------------------------------- ( 3 ) 
Subtracting ( 1 ) from ( 3 ) we get 
0.11685 = 0.5470 cs 
Therefore 
Q.s = 0.2135 L.L<J I ml. 
Putting this value in equation ( 3 ) we get 
0.0463 = 0.00695 Ca+ 0.5488 ( 0.2135) 
67 
( 
Therefore 
C a = 0.1628 I 0.00695 = 23.426 µg I ml. 
Thus concentration of aspirin remaining after one week in the sample is 
23.426 µg I ml. and that of salicylic acid is 0.2135 µg I ml. These were the 
concentrations when the initial sample concentration was 25 µg I ml. 
Similar calculations were done for samples stored upto 6 weeks at 450 C 
and the content of salicylic acid was determined. Similar calculations were 
done for the samples containing aspirin microencapsules. The results 
obtained are summarized in the Table 7 for the samples containing non -
microencapsulated and in the Table 8 for the samples containing aspirin 
microencapsules. 
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TABLE 4: Molar absorptivities of aspirin and salicylic acid 
Com_e_ound 302 nm. 258 nm. 
As_Qjrin 0.02765 0.00157 
Salic_ylic acid 0.00035 0.000695 
( 
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TABLE 5 UV analysis of samples containing non - microencapsulated 
aspirin as an avarage of three measurements. (Powder mix). 
Time interval 258 nm 302 nm. 
Week 1 0.1631 0.002334 
Week2 0.1536 0.0497 
Week3 0.1523 0.0509 
Week4 0.1509 0.0516 
Weeks 0.1489 0.0529 
Week6 0.1477 0.0531 
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TABLE 6 UV analysis of samples containing microencapsulated aspirin as 
an avarage of three measurements (powder mix). 
Time interval 258 nm. 302 nm. 
Week 1 0.1721 0.004218 
Week2 0.1695 0.0501 
Week3 0.1618 0.0529 
Week4 0.1602 0.0566 
Week5 0.1587 0.0581 
Week6 0.1576 0.0598 
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TABLE 7 : UV analysis of samples containing non - microencapsulated 
aspirin as an average of three measurements : 
Time interval As_Q_!rin l_ µg I ml. l Salic_Y!ic acid J µ.g I ml. l 
Week 1 23.426 0.2135 
Week2 21. 759 1.5222 
Week3 21.55 1.567 
Week4 21.35 1.5988 
Weeks 20.98 1.6476 
Week 6 20.877 1.656 
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TABLE 8 : UV analysis of samples containing microencapsulated aspirin 
as an average of three measurements : 
Time interval As_e_irin_{_µg I ml.) Salic_y)ic acid J_µg I ml. l 
Week 1 24.22 0.1610 
Week2 24.047 1.510 
Week3 22.913 1.623 
Week4 22.652 1.760 
Week 5 22.42 1.827 
Week6 22.25 1.881 
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TABLE 9 : Calibration curve data of non - microencapsulated aspirin 
Concentration in_!!__ GI ml. Absorbance 
0 0.000 
5 0.2713 
10 0.4917 
15 0.7810 
20 0.9989 
25 1.5408 
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TABLE 10 : Calibration curve data of microencapsulated aspirin 
( 
Concentration in!!:. G. I ml. Absorbance 
0 0.00 
5 0.3241 
10 0.5243 
15 0.7514 
20 0.9270 
25 1.1359 
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TABLE 11 : Calibration curve data of non - microencapsulated 
acetaminophen. 
Concentration in 1!_ G. I ml. Absorbance 
0 0 
5 0.2376 
10 0.5221 
15 0.8136 
20 0.9915 
25 1.3247 
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TABLE 12 : Calibration curve data of microencapsulated acetaminophen. 
Concentration in 1!_ G. I ml. Absorbance 
0 0.00 
5 0.3052 
10 0.5825 
15 0.7901 
20 1.0116 
25 1.3527 
( 
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TABLE 13 : Calibration curve data of non - microencapsulated 
pseudoephedrine hydrochloride : 
Concentration in J! G. I ml. Absorbance 
0 0 
50 0.048 
150 0.135 
250 0.230 
350 0.293 
550 0.493 
750 0.624 
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TABLE 14 : Calibration curve data of microencapsulated 
pseudoephedrine hydrochloride 
Concentration in mc_g_. I ml. Absorbance 
0 0.00 
50 0.052 
150 0.141 
250 0.228 
350 0.306 
550 0.510 
700 0.645 
( 
APPENDIX D 
Appendix D contains UV absorbance studies on the interaction between 
acetaminophen and pseudoephedrine hydrochloride.( Tables 15 to 18 ). 
( 
2) Interaction of pseudoephedrine with acetaminophen : 
The combination of pseudoephedrine and acetaminophen was found to be 
stable at room temperature as well as accelerated conditions. The 
monitoring was done by UV spectrophotometric analysis. 
Procedure: 
a ) For powder mixes kept at room temperature and accelerated conditions : 
1 ) Weighed 200 gm. of pseudoephedrine and mixed with 200 gm. of 
acetaminophen in a turbula mixture at 90 RPM. for 30 mins. 
2 ) Portions of 200 mg. were taken in 10 ml. open vial. The content uniformity 
of the samples were checked. It was in accordance with USP standards. 
3 ) The samples were withdrawn initially and then at the regular intervals 
and the contents were analyzed spectrophotometrically in 0. 1 N HCL. 
4) The procedure was repeated for microencapsulated pseudoephedrine. 
b ) Compressed tablets at room temperature and accelerated conditions : 
1 ) Granules were prepared by wet granulation method and were 
compressed on the carver press. 
2 ) The tablets characteristics were checked for weight variation, content 
uniformity, hardness, thickness and friability. 
3 ) The tablets were subjected to dissolution test in Vanderkamp 600 
81 
dissolution testing apparatus in 900 ml. of 0.1 N HCL at 100 RPM 
4 ) The samples were removed after 5, 10, 15, 20, 25, 30, 45, 60, and 90 
mins. and analyzed spectrophotometrically at 256 nm. 
5 ) The rate of the interaction was determined in terms of the amount of 
pseudoephedrine remaining with respect to time. 
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TABLE 15 : UV absorbance data of pseudoephedrine hydrochloride and 
acetaminophen mixture in powder mixes at 45 C and 60 % R.H. 
Cone. week 1 week-2 week 3 week 4 week 5 week 6 
50 µg/ml 0.0467 0.0451 0.0450 0.0457 0.0455 0.0451 
150J!9.fml 0.1329 0.1322 0.1311 0.1316 0.1310 0.1303 
250µg/ml 0.2421 0.2419 0.2409 0.2411 0.2409 0.2401 
350µg/ml 0.2969 0.2886 0.2881 0.2879 0.2876 0.2871 
550J!9.fml 0.5022 0.4997 0.4989 0.4981 0.4985 0.4981 
700µg/ml 0.7021 0.7011 0.6994 0.6990 0.6993 0.6995 
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TABLE 16 : UV absorbance data of pseudoephedrine hydrochloride and 
acetaminophen mixture in powder mixes at room temperature : 
Cone week 1 week 2 week 3 week 4 week 5 week 6 
50 µg/ml. 0.048 0.048 0.047 0.046 0.041 0.041 
150µg/ml 0.135 0.133 0.133 0.131 0.131 0.130 
2501!9_/ml 0.230 0.230 . 0.230 0.226 0.226 0.225 
350µg/ml 0.293 0.291 0.291 0.288 0.289 0.289 
5501!9_/ml 0.493 0.488 0.488 0.486 0.485 0.484 
700µg/ml 0.634 0.622 0.622 0.619 0.617 0.609 
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TABLE 17 : UV absorbance data of pseudoephedrine hydrochloride and 
acetaminophen mixture in compressed tablets at 45 C and 60 % R. H. 
Cone. week 1 week 2 week 3 week 4 week 5 week 6 
50 µg/ml. 0.0358 0.0347 0.0342 0.0336 0.0328 0.0319 
150.H:9_/m I 0.1227 0.1229 0.1220 0.1205 0.1211 0.1198 
250.H:9_/m I 0.2856 0.2855 0.2844 0.2736 0.2715 0.2629 
350_gg/ml 0.3319 0.3306 0.3258 0.3244 0.3221 0.3209 
5501!9_/ml 0.5927 0.5919 0.5857 0.5749 0.5699 0.5633 
7001!9_/ml 0.8088 0.8071 0.8027 0.8005 0.7986 0.7926 
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TABLE 18 UV absorbance data of pseudoephedrine hydrochloride and 
acetaminophen mixture in compressed tablets at room temperature : 
Cone. week 1 week 2 week 3 week 4 week 5 week 6 
50 _gg_/ml. 0.0363 0.0352 0.0345 0.0341 0.0339 0.0328 
150µg/ml 0.1215 0.1207 0.1191 0.1136 0.1028 0.1019 
250_gg_/ml 0.2581 0.2491 0.2386 0.2297 0.2163 0.2159 
350_gg_/ml 0.3266 0.3197 0.3171 0.3126 0.3121 0.3122 
550_gg_/ml 0.5712 0.5692 0.5496 0.5478 0.5466 0.5468 
700_gg_/ml 0.7889 0.7811 0.7791 0.7721 0.7714 0.7708 
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